August 03, 2017
Weil is advising Walgreens Boots Alliance, Inc. in a merger agreement pursuant to which a newly formed company controlled by KKR, with Walgreens Boots Alliance as a minority investor, will acquire PharMerica Corporation, a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services. The all-cash transaction is valued at approximately $1.4 billion including the assumption or repayment of debt. The transaction is subject to PharMerica shareholder approval, regulatory approvals, and other customary closing conditions and is expected to close by early 2018. Upon completion of the transaction, PharMerica will become a private company.
The Weil team advising Walgreens Boots Alliance includes Antitrust/Competition Co-Head Steven Newborn, Antitrust partner Jeff White and counsel Vadim Brusser; M&A partner and Corporate Chairman Michael Aiello; Banking & Finance partner Damian Ridealgh; Executive Compensation & Benefits Head Paul Wessel; Tax partner Helyn Goldstein; Corporate associates Vladislava Rebeiz, Andrea Ryken and Philip Wolf; Banking & Finance associate Thomas Mastoras; Executive Compensation & Benefits associate Aaron Cha; and Tax associate Eric Remijan.